

Petr Smisek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8693102/publications.pdf>

Version: 2024-02-01

10
papers

171
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

425
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. <i>Haematologica</i> , 2014, 99, 1472-1478.	3.5	42
2	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019, 104, 1812-1821.	3.5	32
3	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 49-57.	3.5	26
4	A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	25
5	A homozygous deletion in the SLC19A1 gene as a cause of folate-dependent recurrent megaloblastic anemia. <i>Blood</i> , 2020, 135, 2427-2431.	1.4	13
6	Fanconi anemia with biallelic FANCD1/BRCA2 mutations – Case report of a family with three affected children. <i>European Journal of Medical Genetics</i> , 2016, 59, 152-157.	1.3	11
7	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 435-444.	2.0	11
8	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 289-300.	1.6	6
9	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	3.5	3
10	Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 187-198.	1.6	2